Serum Asymmetric Dimethylarginine and Nitric Oxide Levels in Patients with Diabetic Neuropathy

Basit Öğe Kaydı
dc.contributor.authorTamam, Yusuf
dc.contributor.authorUzar, Ertugrul
dc.contributor.authorEvliyaoglu, Osman
dc.contributor.authorTay, Arzu
dc.contributor.authorKilinc, Faruk
dc.contributor.authorCevik, Mehmet Ugur
dc.date.accessioned2024-04-24T17:24:26Z
dc.date.available2024-04-24T17:24:26Z
dc.date.issued2012
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjective: Asymmetric dimethylarginine (ADMA) is a novel marker of endothelial dysfunction. ADMA is an endothelial nitric oxide synthase inhibitor. Due to scarcity of studies on the role of ADMA in pathogenesis of diabetic neuropathy, it remains to be determined whether blood ADMA and nitric oxide (NO) levels are associated with diabetic neuropathy. In this case control study, we aimed to evaluate the relationship between serum NO and ADMA levels among diabetic neuropathy cases Methods: 48 patients with diabetic neuropathy and 34 healthy subjects were included in the study. All type 2 diabetic patients underwent electrophysiological and neurological examination. NO levels were determined using the Griess method. Serum ADMA levels were determined by using the ELISA method. Results: The serum ADMA levels in diabetic neuropathy patients were found to be statistically significantly lower than those of the control group (p=0.005). However, a statistically significant increase was observed in serum NO levels in patients with diabetic neuropathy compared with those in the control group (p=0.009). A negative correlation was found between NO levels and ADMA levels (p=0.041, r=-0.23). Discussion: Changes in NO and ADMA levels in the blood of diabetic neuropathy patients may indicate oxidative stress and endothelial dysfunction in the pathogenesis of diabetic neuropathy. (Archives of Neuropsychiatry 2012; 49: 183-187)en_US
dc.identifier.doi10.4274/Npa.y6233
dc.identifier.endpage187en_US
dc.identifier.issn1300-0667
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-84866147344
dc.identifier.scopusqualityQ3
dc.identifier.startpage183en_US
dc.identifier.trdizinid162962
dc.identifier.urihttps://doi.org/10.4274/Npa.y6233
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/162962
dc.identifier.urihttps://hdl.handle.net/11468/19677
dc.identifier.volume49en_US
dc.identifier.wosWOS:000309102600004
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.language.isoenen_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofNoropsikiyatri Arsivi-Archives of Neuropsychiatry
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectDiabetic Neuropathyen_US
dc.subjectNitric Oxideen_US
dc.subjectAdmaen_US
dc.subjectOxidative Stressen_US
dc.subjectEndothelial Dysfunctionen_US
dc.titleSerum Asymmetric Dimethylarginine and Nitric Oxide Levels in Patients with Diabetic Neuropathyen_US
dc.titleSerum Asymmetric Dimethylarginine and Nitric Oxide Levels in Patients with Diabetic Neuropathy
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu